In Brief This Week: Syapse; Amoy Diagnostics; Precision Therapeutics, Med BioGene; Abbott | GenomeWeb

NEW YORK (GenomeWeb News) – Syapse, a Palo Alto, Calif.-based startup developing software for interpreting next-generation sequencing data to diagnose and treat patients, has raised $3 million in Series A venture capital funding. The firm will use the funds to hire between eight and 10 software developers who will help the company continue development of its flagship product, Syapse Discovery, a web-based tool intended for companies and labs running NGS-based diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.